Wave Life Sciences Stock Earnings Reports

Wave Life Sciences reported significant progress across its lead programs and strong cash runway. Key clinical advances: WVE-007 (INHBE GalNAc siRNA for obesity) is being accelerated after Phase I signals of meaningful visceral fat reduction, muscle preservation, durable target suppression (supporting once- or twice-yearly dosing) and FDA acceptance of the multi-dose portion of the INLIGHT study; the Phase IIa multi-dose trial (240 mg and 400 mg; four cohorts of 40 each, with and without T2D) is expected to start this quarter and additional combination and maintenance studies with incretins will begin this year. WVE-006 (RNA editing AIMer for alpha-1 antitrypsin deficiency, AATD) has shown restoration of functional M-AAT, including >20 µM AAT during acute phase responses in interim data; the company is preparing for regulatory interactions and expects feedback mid-2026 on a potential accelerated approval pathway. WVE-008 (RNA editing for PNPLA3 I148M homozygous liver disease) is being advanced toward a CTA this year. Other pipeline: continued work on bifunctional modalities, additional hepatic and extrahepatic candidates, and an exon-skipping DMD program with continued development toward a monthly regimen and potential partnering for commercialization. Financials: Q1 2026 revenue was $38.2M (vs. $9.2M y/y, reflecting regained rights to WVE-006 and GSK collaboration progress); R&D $47.4M, G&A $22.1M; net loss $26.1M (improved vs. prior year). Cash and equivalents were $544.6M, which management expects funds operations into Q3 2028. Upcoming catalysts include expanded WVE-006 data at ATS (May 18) and an investor webcast, additional Phase I 007 cohorts (including 600 mg), initiation of the Phase IIa 007 multi-dose portion this quarter, combination/maintenance 007 studies later this year, and CTA/clinical start plans for WVE-008 in 2026. Risks highlighted: standard forward-looking statement cautions and regulatory/clinical uncertainties.